Certara Debuts Phoenix™ Version 8.5 Software to Advance Drug Development

RADNOR, Pa. – Certara, Inc., a pioneering company dedicated to accelerating drug development through biosimulation, has officially announced the rollout of Phoenix™ version 8.5. Positioned as the touchstone software in pharmacokinetic/pharmacodynamic (PK/PD) and toxicokinetic modeling, Phoenix is integral to the research and development processes within the pharmaceutical sector. This new release affirms Certara's commitment to innovation, enhancing the efficacy and efficiency of drug development.

Key Enhancements in Phoenix™ Version 8.5

Phoenix™ version 8.5 showcases several advancements that are expected to streamline drug development workflows and improve predictive modeling. With tools designed to provide more precise simulations and analytics, researchers can now approach drug development with greater confidence in the potential outcomes, thereby reducing time to market and associated costs.

Impact on Drug Development Industry

As drug development continues to face scrutiny for efficiency and cost-effectiveness, solutions like Phoenix™ version 8.5 are vital. Such technological advancements play a crucial role in not only accelerating the development cycle but also in potentially enhancing patient outcomes through more personalized medication strategies.

Investor's Perspective

The launch could signal a continued momentum for Certara's growth and might be of interest to investors closely watching the biotech and health informatics sectors. Represented on the stock market by the ticker symbol CERT, Certara Inc. remains a noteworthy conversation on the potential of innovation to drive both scientific advancement and shareholder value.

Based in Princeton, New Jersey, Certara Inc. continues to serve clients globally, focusing on the integration of software products and technology services across various stages of drug discovery and development.

software, pharmaceuticals, investing